January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new radiotracer, 2-18F-fluorodeoxysorbitol (18F-FDS), can identify and track bacterial infection in lungs better than current imaging methods and is able to differentiate bacterial infection from inflammation.

Canon Medical Systems Europe B.V. announced the change of ownership of DelftHold B.V. following its acquisition of the company by Canon Europa N.V. DelftHold BV specializes in enterprise healthcare information technology (IT) solutions, (manufacturing) digital X-ray systems, system integration and service for a varied portfolio of customized total solutions for radiology departments.

On Jan. 8, 2018, Robotics Outpatient Center, Los Angeles (ROC-LA), became the first outpatient surgery center in the United States to purchase the Globus ExcelsiusGPS system for robotic surgery guidance and navigation.

QualiTest Group recently announced its improved Virtual Radiology Environment (VRE) testing solution for picture archiving and communication systems (PACS). The offering builds upon the original solution with enhanced crowd testing and artificial intelligence (AI) capabilities, enabling vendors to scale more quickly.

Virtual Radiology Environment

January 22, 2018 — A registry that tracks the quality of medical care provided to patients receiving cancer treatment launched this month as part of a collaboration between the American Society of Clinical Oncology (ASCO) and the American Society for Radiation Oncology (ASTRO).

January 19, 2018 — SonoSim Inc. has officially launched a comprehensive OB-GYN ultrasound training solution in support of a recently announced consensus-based training curriculum. SonoSim's cloud-based training platform is intended to help educators implement a newly announced and widely endorsed OB-GYN training curriculum and competency assessment recommendations.

January 19, 2018 — New Appropriateness Criteria (AC) Patient Summaries from the American College of Radiology (ACR) can help patients better understand which imaging tests may be best for their condition or why they may not need an imaging exam at all.

January 19, 2018 — Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity. Through this new, internally-funded program, Ligand intends to advance products toward proof-of-concept, followed by selling or out-licensing them for further development and commercialization.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now